Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN.
ANSAID vs BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Category C
Category D/X
NSAID
NSAID / Antiplatelet